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– An ascites-bearing, metastatic ovarian cancer model was created in mice
– For the first time, cytometry by time of fly (CyTOF) technology was used to
delineate the immune landscape of the ascitic fluid
– Our data suggest that the application of this innovative tool will benefit
advanced ovarian cancer diagnosis and treatment.
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Background: Ovarian cancer (OC) is typically diagnosed late, associated with
high rates of metastasis and the onset of ascites during late stage disease. Under-
standing the tumormicroenvironment and how it impacts the efficacy of current
treatments, including immunotherapies, needs effective in vivo models that are
fully characterized. In particular, understanding the role of immune cells within
the tumor and ascitic fluid could provide important insights into why OC fails to
respond to immunotherapies. In this work, we comprehensively described the
immune cell infiltrates in tumor nodules and the ascitic fluid within an opti-
mized preclinical model of advanced ovarian cancer.
Methods: Green Fluorescent Protein (GFP)-ID8 OC cells were injected
intraperitoneally into C57BL/6 mice and the development of advanced stage OC
monitored. Nine weeks after tumor injection, mice were sacrificed and tumor
nodules analyzed to identify specific immune infiltrates by immunohistochem-
istry. Ascites, developed in tumor bearing mice over a 10-week period, was char-
acterized by mass cytometry (CyTOF) to qualitatively and quantitatively assess
the distribution of the immune cell subsets, and their relationship to ascites from
ovarian cancer patients.
Results: Tumor nodules in the peritoneal cavity proved to be enriched in T cells,
antigen presenting cells and macrophages, demonstrating an active immune
environment and cell-mediated immunity. Assessment of the immune landscape
in the ascites showed the predominance of CD8+, CD4+, B–, and memory T
cells, among others, and the coexistance of different immune cell types within
the same tumor microenvironment.
Conclusions:We performed, for the first time, amultiparametric analysis of the
ascitic fluid and specifically identify immune cell populations in the peritoneal
cavity of mice with advanced OC. Data obtained highlights the impact of CytOF
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as a diagnostic tool for this malignancy, with the opportunity to concomitantly
identify novel targets, and define personalized therapeutic options.
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1 INTRODUCTION
Ovarian cancer (OC) is the 7th most common cause of
death in women worldwide, with over 21 000 new cases
expected in the United States in 2020.1 Survival rates vary
according to the stage of disease, with a 5-year survival rate
of around 30% for advanced cancers,2,3 the most common
ofwhich is high-grade serous ovarian carcinoma (HGSOC)
accounting formore than 50% of cases. Unfortunately, only
33% of OC cases are identified early, the majority being
diagnosed at a later, more advanced stage, and associated
with a significantly worse prognosis.4
According to the National Comprehensive Cancer Net-
work (NCCN) guidelines, the standard of care ther-
apy for HGSOC involves debulking surgery followed
by platinum- or taxol-based chemotherapies. Among
other recommended treatments, liposomal doxorubicin
is a viable option for both early and advanced-stage
disease.5 Targeted therapeutic approaches, recently added
to standard clinical practice, provide improved sur-
vival rates and include: vascular endothelial growth fac-
tor (VEGF)-A inhibitors,6 and poly (ADP-ribose) poly-
merase (PARP) inhibitors, which are indicated for patients
with a BReast CAncer gene (BRCA1/2) mutation.5 OC
remains a complex disease to treat, owing to the high
chemotherapy-resistance emergence rate,7 and in recent
years great emphasis has been placed on the employ-
ment of immunotherapies to combat this issue, although
currently no clinically approved immunotherapy for
HGSOC exists. Modest activity within recurrent OC
patients (which included epithelial, fallopian, or pri-
mary peritoneal OC) has been reported in the Phase II
KEYNOTE-100 study for the checkpoint inhibitor (CPI)
Pembrolizumab.8 Additionaly, several Phase III trials are
exploring the combination of CPI with PARP or VEGF
inhibitors to determine any therapeutic synergies.9
Limited immunotherapy efficacy observed to date, how-
ever, could be explained by the typically “cold” immune
status of OC. Indeed, the advanced OC tumor microen-
vironment (TME) is characterized by a lack tumor infil-
trating lymphocytes (TILs) and failed T-cell priming due
to a combination of poor antigen presentation and an
intrinsic insensitivity to T-cell killing.10,11 More specifi-
cally, tumor growth is associated with a scarcity (if not
total absence) of CD8+ T cells within the TME,12 or the
inability of dendritic cells (DCs) to effectively present
antigen and stimulate a cytotoxic response.13 One of the
possible mechanisms behind DC inactivation has been
provided by Cubillos-Ruiz et al.14 The authors demon-
strated that the reduced capability of DC to support an
anticancer immune response is associated to the tran-
sient, yet abnormal lipid accumulation in the endoplas-
mic reticulum, which obstructs their normal antigen-
presenting capacity.14 Another factor proposed to play a
role in ovarian cancer progression at advanced stages and
resistance to immunotherapy is the presence of transform-
ing growth factor-β (TGF-β). Specifically, TGF-β is a potent
immunosuppressor within the tumor environment being
involved in several tumor-associated processes, includ-
ing the increase of the epithelial to mesenchymal transi-
tion, the promotion of angiogenesis and immune suppres-
sion. The enhanced secretion of TGF-β within the tumor
microenvironment is associated to the recruitment of reg-
ulatory T cells via expression of FoxP3, which ultimately
results in diminished cytotoxic T-lymphocytes and in a
reduced presence of DCs.15,16 There is, however, a paucity
of evidence on the specific roles of immune cell popula-
tions within the OC TME. Hence, a more comprehensive
understanding of the immune cell landscape would pro-
vide an important platform for the development of more
efficacious immunotherapeutic strategies.
The accumulation of fluid within the peritoneal cav-
ity (ascites), which contains a variety of soluble and
cellular components, is characteristic of advanced stage
OC. Indeed, more than one third of OC patients present
with ascites at diagnosis, which has been correlated with
its spread within the peritoneal cavity and poor patient
prognosis.17 The accumulation of ascites occurs as a con-
sequence of unbalanced drainage of the peritoneal cav-
ity, due to obstruction of the lymphatic system by cancer
cells,17 or by increased leakage of fluid from the microves-
sels lining the peritoneum.18 Ascites build-up also con-
tributes to malignant progression by facilitating multifocal
cancer cell dissemination on the peritoneal surface.19 The
presence of an intraperitoneal ascitic current, which acts
as a means of transport of OC spheroids, further facilitates
peritoneal, lymphatic, and hematogenous metastasis,20 a
phenomenon that falls within the multistep process of
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metastatic dissemination. Soluble and cellular compo-
nentswithin the ascitic fluid have also been shown to influ-
ence metastatic behavior.17 Soluble components, includ-
ing growth factors, cytokines, chemokines, and extracel-
lular matrix pieces, inhibit T helper cell proliferation21
and DC maturation22 mediated by IL-10. Cellular compo-
nents, such as resident tumor cells or tumor-associated
fibroblasts, or nonresident immune cells, on the other
hand, have a wide ranging impact on the TME. The
presence, functionality, and effect of specific, singularly
taken immune cell populations within the ascitic fluid has
beenwidely described, unraveling the association between
the presence of tumor-infiltrating CD8+ T cells and the
prolonged disease-free survival,23 or unmasking the role
of T regulatory cells in creating an immunosuppressive
environment.24 As such, ascites represents a potentially
very informative source of information regarding the effect
of immune cells on metastatic disease progression. More-
over, its presence in over 30% of patients at diagnosis ren-
ders it an important issue to tackle and explore. Hence, a
complete profiling of the ascites immune content would
prove useful if done on patients in a tailored fashion. How-
ever, fundamental research on the biological interactions
of the components of advancedOC ascites requires reliable
in vivo models.
In this study, we optimize the development of an
advanced OC model in immunocompetent mice to fill the
gap in the understanding of the immune landscape within
the peritoneal cavity. For the first time, we apply mass
cytometry to comprehensively describe the immunological
TME within the ascites and to provide insights about the
effectiveness of the selected preclinical model in reproduc-
ing the human tumor immunomicroenvironment. Finally,
we propose mass cytometry as an accurate strategy for the
development of personalized strategies against advanced




The ID8 cell line, originated from mouse ovarian sur-
face epithelial cells (MOSEC), was purchased fromMerck-
Millipore. Cells were cultured in High Glucose Dulbecco’s
Modified Eagle medium (HG-DMEM) (Sigma) supple-
mentedwith 10% fetal bovine serum (FBS, ThermoFisher),
5 μg/mL insulin, 5 μg/mL transferrin and 5 ng/mL sodium
selenite (1× ITS, Sigma) and 1× Penicillin-Streptomycin
Solution (Sigma). Culture conditions were 37◦C in a
humidified 5% CO2 atmosphere.
2.2 Lentivirus transduction, lentiviral
infection of ID8 cells with the luciferase
vector and cell line selection
The ID8-Luc/GFP cell line was generated by transduction
with Lentivirus particles containing the CMV promoter
for the expression of humanized firefly luciferase (hLUC)
and the SV40 promoter for the expression of GFP pro-
tein according to manufacturer’s protocol (GeneCopoeia).
Briefly, ID8 cells were plated at 2 × 104 cells per well (12-
well plate, Corning) and incubated overnight at 37◦C in a
humidified 5% CO2 atmosphere. Cells were then infected
with 10 MOI of Lenti-PAC™ plasmid mix (GeneCopoeia
Inc.) in the presence of 8 μg/mL polybrene (Sigma). After
overnight incubation at 37◦C/5% CO2, the viral super-
natant was discarded, and cells were washed with 1×
PBS (ThermoFisher) prior to the addition of warmed HG-
DMEM media. Three days after infection, cells with high
levels of GFP expression were selected by Cell Sorter NIR
Aria II (BD Bioscience) and expanded for a week in HG-
DMEMmedia in presence of 1 μg/mL puromycin (Invitro-
gen) to further select transfected cells and generate a stable
cell line.
2.3 In vivo propagation of ID8-GFP
tumors
Female C57BL/6 (5-6 weeks old) were purchased from
the Charles Rivers laboratories. All animal studies were
carried out in accordance with guidelines determined by
the Animal Welfare Act and the Guide for the Care and
Use of Laboratory Animals and complied with protocols
approved by the Institutional Animal Care and Use Com-
mittee at the Houston Methodist Research Institute (AUP-
0219-0013). Briefly, C57BL/6 female mice were divided into
3 groups (n = 5 mice per group) and injected intraperi-
toneally with 5× 106, 1× 107, or 1.5× 107 ID8-Luc/GFP cells
in 200 μL of PBS. Cells were injected into the lower right
quadrant of the abdomen. Mice weights (g) were recorded
daily following ID8-Luc/GFP cell injection and plotted as
fold change. Representativemacroscopic images of tumors
and ascites development were taken with a smartphone
camera.
2.4 Bioluminescence, imaging, and
tumor localization within the abdominal
cavity
To track tumor growth, luciferase luminescence was
detected using a Xenogen IVIS Spectrum imaging system
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(PerkinElmer) as previously described.25 Briefly, 200 μL
of 15 mg/mL D-luciferin was injected into the mice
abdomen and the bioluminescent signal evaluated after
10 min to obtain the peak photon emission per sec-
ond. The signal was quantified using the Living Image
software (PerkinElmer) and the total photon flux emis-
sion (photons/second) in the regions of interest (ROI)
recorded, starting at day 8 after tumor cell injection.
Images were normalized using the Living Image software
(PerkinElmer)with aminimumandmaximum radiance of
1.7 × 104 and 9.7 × 104 photons/s, respectively.
2.5 Hematoxylin and eosin (H&E)
staining and immunohistochemistry (IHC)
Sixty-three days after ID8-Luc/GFP cell injection, mice
had a strong tumor signal intensity by IVIS. Hence, mice
were sacrificed and the peritoneal membrane, abdominal
tumors, and liver were sampled, fixed in 4% paraformalde-
hyde solution overnight, and embedded in paraffin. Paraf-
fin embedded tissues were subsequently sectioned at a
thickness of 5 μm and hematoxylin and eosin (H&E) stain-
ing performed to enable general inspection of the tissues.
The 5 μm thick sections were also used for immunohisto-
chemical staining. Sections were incubated with primary
anti-CD3 (rabbit, Dako), anti-MHC-II (rat, eBioscience), or
anti-F4/80 (rat, BioRad) for 1 h at room temperature (RT)
in a moist chamber. Sections were imaged with a EVOS R©
FL Auto Imaging System (Life Technologies).
2.6 Ascites extraction and mass
cytometry by time of flight (CyTOF)
analysis
Seventy days after tumor cell injection with 1 × 107
ID8-Luc/GFP cells, mice started developing ascitic fluid.
Ascites onset was detected by abdomen palpation, by
eye and by weight increase. After reaching a weight of
30 g, three mice were sacrificed, and the ascetic fluid
collected by syringe suction following abdominal incision.
Ascitic fluid was centrifuged, and red blood cells lysed
by incubation in Ammonium-Chloride-Potassium (ACK)
lysing buffer (ThermoFisher) for 10 min at RT. Immune
cell enrichment was achieved using Percoll gradient
centrifugation. Briefly, the cell pellet was resuspended
in 85% Percoll (GE Healthcare), then carefully layered
onto 50% Percoll and centrifuged at 620 × g without the
brake for 30 min at 4◦C. After centrifugation, three layers
of cells were present. The middle layer, consisting of the
immune cells of interest, was recovered and used for
mass cytometry staining. Cell viability was determined
TABLE 1 Panel of the antibodies selected for mass cytometry,



































by incubation with 25 μM cisplatin for 5 min. At these
conditions, cisplatin preferentially reacts with proteins in
dead cells and it widely established as a viability reagent
for mass cytometry.26 After washing in Maxpar R© Cell
Staining Buffer (Fluidigm), cells were resuspended in 40
μL surface-staining antibody (Ab) mix and incubated at
RT for 30 min. Antibodies were purchased from Biolegend
(except for Arginase-1 and NOS2, which were purchased
from eBioscience) and conjugated to the metals using
the Maxpar R© X8 Multimetal Labeling Kit (Fluidigm).
Selected Ab are shown in Table 1. Cells were then washed
2× and fixed with 100 μL of Fix/Perm buffer (eBioScience)
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for 10 min, followed by the addition of 200 μL Perm buffer
(eBioScience) for 10 min. The intracellular staining was
performed by diluting cells in 50 μL Ab mix and incubat-
ing them at RT for 60 min. After the washing steps, the
cell ID DNA intercalator (500 μM, Fluidigm) was added
to cells in a 1:1000 dilution for 30 min at RT. Cells were
then washed, counted, and filtered through blue-capped
tubes (35 μm) before resuspension in 50 μl deionized
water and the addition of 50 μl of EQ-beads (eBioScience).
Samples were acquired by Helios CyTOF machine. A total
of 100 000 events were recorded for each sample, and
subsequently analyzed on Cytobank. Immune cell pop-
ulations were identified by manual gating. The intensity
of the signal in the viSNE plots obtained was divided into
three main groups. The following thresholds were used for
categorization of the immune cell subtypes and applied
to each specific viSNE plot: if the majority of the region
was in the high range of expression (the red colored area,
with numerical values varying according to the analyzed
marker), the marker was considered highly expressed
(++); if the region was in the middle range of expression
(color-coded azure to orange) then the marker was con-
sidered to be moderately lowly expressed (+). Finally, if
the area exhibited mostly lower expression (indicated by
blue and dark blue colors), markers were considered not
expressed (−).
2.7 Statistical analysis
Statistical analysis was performed by ANOVA for all
experiments that required it. More specifically, a two-way
ANOVA with post hoc Dunnett comparisons to week 1 or
Day 0 was employed for tumor signal and tumor weight
analyses, respectively. Data with a P < 0.05 were consid-
ered significant (∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001). All
results were obtained from independent experiments and
expressed as the mean± standard deviation (SD).
3 RESULTS
3.1 Tumor model optimization
After ID8-Luc/GFP cells (5 × 106, 1 × 107 or 1.5 × 107) were
intraperitoneally injected, tumor growthwas assessed over
a 9-week period. After 9 weeks, animals injected with
1 × 107 cells showed a 13.6 ± 9 fold increase in tumor
growth, based on fluorescence signal, compared to week
1 (P < 0.001), as quantified by IVIS (Figure 1A). Mice
injected with 5 × 106 or 1.5 × 107 cells showed a 8.2 ± 4
fold and 5.6 ± 43.9 fold increase in tumor growth, respec-
tively, again based on fluorescence signal, compared to
week 1 (P < 0.001). No differences in tumor growth were
noted between the three treatment groups, although all
three groups showed increased tumor size over time. Rep-
resentative pictures of the signal produced by the tumor
within the abdomen are shown in Figure 1B. Figure 1C
shows the fold variation of mice weights over the 9-week
period, indicating a correlation between tumor growth and
mouse weight, which was particularly evident following
injection of 1 × 107 or 1.5 × 107 cells. Statistical difference
was seen within groups at different time points when com-
pared to the day of injection (P < 0.001). This difference
becamemoremarked after day 23 days in 5× 106 group and
after 37 days in 1 × 107 group. No statistically significant
intragroup differences were recorded in 1.5 × 107 group.
Sixty-three days after tumor cell injection, mice were sac-
rificed and organs extracted to better localize the tumors
within the abdomen. ID8-Luc/GFP cells were identified
in several abdominal organs including liver, kidneys, and
spleen, and multiple tumor nodules/formations were ran-
domly distributed around the abdominal cavity within the
peritoneum (Figure 1D).
3.2 Histological analysis of liver and
tumor nodules
Tumors, extracted at day 63 after intraperitoneal injec-
tion, were processed and stainedwithH&E. Tumor growth
occurred in two main areas; firstly the inner surface of the
peritoneal membrane, as can be inferred from nodules vis-
ible inmice from the 1× 107 group (Figure 2A), and second,
the abdomen, wheremultiple tumormasses were found in
multiple organs of the lower abdomen (Figure 2B). H&E
staining of the liver, peritoneal membrane, and tumor
masses within the abdominal cavity shows the presence of
tumor growth within all three treatment groups and illus-
trates the extent of tumor infiltration throughout the peri-
toneal cavity (Figure 2C).
3.3 Immunohistochemistry of immune
infiltrates within tumors
Tissue sections were also analyzed by immunohistochem-
istry (IHC) to identify immune cell infiltration within
tumors found on the peritoneal membrane. The presence
of cell surface markers for T cells, antigen presenting
cells (APC), and macrophages (CD3, MHC-II, and F4/80,
respectively) was investigated in mice from all treatment
groups (Figure 3). Significant immune cell infiltration was
apparent in tumors present in all the treatment groups. Of
note, therewere high numbers of T cells andmacrophages,
indicating an active immune environment.
6 of 18 PISANO et al.
F IGURE 1 Tumor model generation and optimization. (A) Tumor growth signal quantification over a 9-week period by IVIS following
injection of 5 × 106, 1 × 107, or 1.5 × 107 cells (n = 5). (B) Representative IVIS images of each tumor group taken after 6 weeks from tumor cells
injection. (C) Mice weights (grams), expressed as fold change, during the 9-week experimental period (n = 5). (D) IVIS images of organs
extracted from the mice abdomen 9 weeks after injection with 5 × 106, 1 × 10 7, or 1.5 × 107 ID8-Luc/GFP cells. Extracted organs include liver,
spleen, kidneys, lungs, heart, peritoneal membranes, tumor nodules. Epi-fluorescent signals reflects the presence of ID8-Luc/GFP cells. Data
are expressed as mean (SD) from 5 independent experiments. Data were analyzed by ANOVA and Dunnett’s pairwise multiple comparison
test; values differ from week 1 (A) or day 0 (C), *P < 0.05, **P < 0.01, ***P < 0.001
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F IGURE 2 Histological assessment and localization of tumor nodules within the peritoneal cavity. (A) Representative images of tumor
growth on the peritoneal membrane (green arrows). (B) Representative images of tumor growth within the lower abdominal cavity, indicated
by the green arrow in the inset image. (C) H&E staining of tumor nodules found in the liver, peritoneal membrane, and abdominal cavity
(black arrows). Magnification: 10×, scale bar: 400 μm
A similar trend of immune cells recruitment to the
tumor masses was observed in the cancerous fragments
extracted from different areas of the abdominal cavity. Fig-
ure 4 shows a strong presence of immune infiltrates despite
the varied histological landscapes of the tissues examined.
3.4 Immune characterization of ascites
through mass cytometry (CyTOF)
To obtain a better understanding of the immune landscape
of our metastatic OC model, immune cell populations
within the ascites of tumor-bearing mice were analyzed
by mass cytometry. Seventy days after tumor cell injection,
ascitic fluid formation resulted in a swollen abdomen
that was apparent and palpable (Figure 5A). Differen-
tial expression analysis of specific immune cell surface
markers (Table 1) present on CD45+ cells within ascitic
fluid was performed through mass cytometry (CyTOF)
analysis. Results from this analysis are plotted onto a
viSNE graph (Figure 5B) that plots CD45+ cells on a
two-dimensional map and identifies individual cells by
their expression of the specific immune cell markers cho-
sen (for gating strategy, see Figure S1). From these data,
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F IGURE 3 Identification of immune cell infiltration within tumors of the peritoneal membrane. Representative IHC images of each of
the experimental groups showing the presence of CD3+, MHC-II+, and F4/80+ cells (T cells, APC, and macrophages, respectively) within
tumors on the peritoneal membrane. Black arrows indicate the tumor masses. Magnification: 20×, scale bar: 200 μm
immune cell population percentages and numbers can be
derived (Figure 5C) enabling a comprehensive analysis
of the ascitic fluid immune cell population. Within the
present study, the most abundant cell populations in the
ascitic fluid of tumor-bearing mice were B cells (27.3.6%
± 9.6%), CD8+ T cells (38.5% ± 4.5%), and CD4+ T cells
(20.7% ± 3.5%), with myeloid immune cells, including
monocytes, macrophages, DCs, eosinophils, and neu-
trophils accounting for the remaining 15% of the total cell
population.
Further characterization revealed the presence of spe-
cific subpopulations among CD8+ and CD4+ T cells (Fig-
ure 5D). Specifically, based on their expression of specific
markers we identified the presence of (i) memory CD8+
T cells (Ly6C+/CD44+, 23.1% ± 12.1%), (ii) T helper cells
(IFNγ+/CD4+, 22.2% ± 15.3%), and (iii) cytotoxic T lym-
phocytes (CTL, IFNγ+/CD8+, 12.5% ± 9.05%). In addition,
low expression of PD1 in 8.03%± 7.4% of CD4+ T cells and
2.3% ± 1.5% of CD8+ T cells was noted indicating a low
level of T-cell exhaustion. The percentages of remaining
CD8+ and CD4+ T cells with no identified subpopulations
were 61.9% ± 24.3% and 69.7% ± 28.5%, respectively. The
CD8+/CD4+ T-cell ratio was 1.65, indicating a prevalence
of CD8+ T cells, while the relative percentages of T helper
and CTL cells (4.6% ± 3.1% and 4.85% ± 3.4%, respectively)
were similar.
Table 2 shows the list of all markers identified in each
immune cell population and differentiates them based
on the level of expression (see Section 2.6). For instance,
the B-cell group is characterized by the high expression
of the markers CD38, B220, MHC-II, CD19, and CD80.
In addition, CD25, PD-L1, and PD-1 are found to be
expressed by both B cells and CD4+ and CD8+ cells at
high and low expression levels, respectively. CD4+ and
CD8+ cells share high expression levels of TCRβ and
IFN-γ (in addition to the cell specific markers CD4 and
CD8α, respectively), with Ly6C, Tbet, CD25, and CD103
being specifically expressed by the CD8+ population. Treg
cells express high levels of Foxp3, CD25, CD4, and CD44
markers among others, with CD44 being also present in
eosinophils, NK cells, monocytes, macrophages, DCs, and
neutrophils. Macrophages show high expression of F480
and share with monocytes the moderate to low expression
of CD11b, TCRgt, CD64, and CD80. Similarly, the presence
of CD11b, Ly6C, and Ly6G is observed in both, eosinophils,
and neutrophils.
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F IGURE 4 Identification of immune cell infiltrates within abdominal cavity tumors. Representative IHC images of CD3+, MHC-II+,
F4/80+ cells (T cells, APC, and macrophages, respectively) within tumor nodules (indicated by black arrows) found within the abdominal
cavity. Magnification: 20×, scale bar: 200 μm
To complement the information provided in Table 2
and visualize the immune cell marker expression, data
from the CyTOF experiments were arranged into sub-
groups according to marker expression and their associ-
ation with specific cell types (Figure 6). Several immune
markers were associated with more than one cell popula-
tion; however, the three main cell types identified were:
B cells; CD4+ and CD8+ T cells; neutrophils, eosinophils,
macrophages, monocytes, and dendritic cells. The expres-
sion of CD62L, iNOS, and CD206 was not apparent on any
cell population.
4 DISCUSSION
The treatment of advanced OC is challenging, espe-
cially considering the altered physical transport properties
that create an immunosuppressive environment27,28 and
limit responsiveness to current immunotherapy strategies.
Efforts to optimize animal models that comprehensively
mimic cancer development in vivo and thus enable new
therapeutic strategies to be tested are ongoing. In this con-
text, the mouse ovarian surface epithelial cell line (ID8
cell line) is widely used to generate preclinical models of
advanced OC. This is due to its capacity to closely repro-
duce the histopathological nuances that are characteris-
tic of patients with advanced OC. These include tumor
dissemination across the peritoneal cavity, a specific pat-
tern of invasion and the formation of ascites, which fur-
ther increases the metastatic process and hinders therapy
effectiveness.29 In addition, ID8 cells have been found to
express Pax8,30 a member of a transcription factor family
that has also been linked to a role in OC development.31
Lastly, the immunological nature of ID8-based OCmodels
further increases their clinical relevance as they also allow
for the testing of innovative immunotherapies with the
potential to treat this malignancy. As such, ID8 cells have
beenwidely used to test different hypotheses. For example,
Wilson et al used the ID8 model to track nuclear factor-
kappa B (NF-κB) signaling during cancer progression,32
while Zhang et al used ID8 cells stably expressing the vas-
cular endothelial growth factor to demonstrate increased
tumor-progression rate and ascites formation.33 However,
some doubts about the stability of this cell line have been
raised, since the onset of ascites has been reported to alter
the efficacy of the bioluminescent signaling associated to
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F IGURE 5 Characterization of immune cell populations in ascites. (A) Representative image of ascites formation in tumor-bearing
C57BL/6 mice 70 days after tumor cell injection. (B) visNE plot obtained by mass cytometry depicting the most represented immune cell
populations in ascites collected from tumor-bearing mice (n = 3). (C) Immune cell populations identified from the mass cytometry analysis as
a percentage of the total cells. (D) Percentages of CD4+ and CD8+ T-cell subtypes, which are mainly CD4+/CD8+/IFNγ+,
CD4+/CD8+/PD1+, or CD8+/LyC6+/CD44+. Data presented are mean (SD)
ID8-Luc/GFP cells.34 Moreover, despite ID8 cells being
considered the gold standard when generating advanced
OC in immune competent mice,35 the scientific commu-
nity is yet to provide robust protocols, nor a consensus
on optimal cell concentrations and incubation times for
tumor development. In particular, the literature reports a
wide range of ID8 cell concentrations being peritoneally
injected (between 1 × 106 and 1 × 107),32,36–39 and different
incubation times required to develop a noticeable tumor
and ascites in immunocompetent mice.34,39
In this work, we tested three concentrations of ID8-
Luc/GFP cells (5 × 106, 1 × 107, or 1.5 × 107 cells) for
their capacity to develop an advanced tumor in immune-
competent mice after intraperitoneal injection, with the
aim of identifying a robust, reproducible protocol for
tumor development. The range of concentrations selected
was based on the most remarkable results found in lit-
erature, that is, significant tumor and acsities develop-
ment. Our results demonstrated significant tumor growth
over a 9-week period for each of the cell concentrations
tested, suggesting the suitability of these cell concentra-
tions to reliably create a tumor in vivo. Additionally, the
onset of asciteswas confirmed between 70 and 80 days after
cell injection, which was associated with increased mouse
weight providing an indication of advanced stage disease.
H&E staining confirmed the presence of distinct tumor
nodules on the liver, scattered across the abdominal cav-
ity and lining the peritoneal membrane. No differences in
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F IGURE 6 viSNE plots for 33 immune markers. From the CyTOF analysis of the 33 immune cell markers, three main immune cell
populations were identified based on the coexpression of specific markers. B cells: CD38+/B220+/MHC-II+/TNFα+/CD19+/CD80+. T cells
(CD4+ and CD8+): CD25+/PD-L1+/ PD-1+ have been colocalized on both, CD4+ and CD8+ cells, which also express subgroup-specific
markers TCRβ, IFN-γ, CD4, CD8α, Tbet, and CD103. The third subgroup is represented by neutrophils, eosinophils, macrophages, monocytes,
and dendritic cells, which are specifically positive for NK1.1, CD11c, Ly6G, SiglecF, and FoxP3. The markers CD86, F480, CD11b, and CD64 are
shared with the B cells subgroup, whereas RORgtm Ly6C, TCRgt, and Arg-1 are shared with the CD4+/CD8+ cell subgroup
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cells Monocytes Neutrophils Eosinophils Macrophages
Dendritic
cells
CD38 ++ − − + − + + − + +
B220 ++ − − − − − − − − −
CD25 + + − ++ − − − − − −
TCRb − ++ ++ ++ − − − − − −
IFN-γ + ++ ++ − − − − − − +
MHC-II ++ − − + − − − − + +
TNF-α + − − − − − − − − −
PD-L1 ++ + + + − − − − + +
CD4 − − ++ ++ − − − − − −
Tbet − + − − + − − − − ++
CD19 ++ − − − − − − − − −
CD80 ++ − − − − + + + + −
PD-1 + + + + − − − − − −
CD8a − ++ − − − − − − − −
CD103 − + − + − − − − − −
CD86 + − − + − + + + − −
F480 − − − − − + + + ++ −
CD45 − − − − − − − − − −
RORgt − + − − − − − + − −
Ly6C − + − − − ++ ++ ++ − −
CD11b + − − − − + ++ ++ + ++
CD64 − − − − − + − − + −
CD44 ++ ++ + ++ ++ ++ ++ ++ ++ ++
TCRgt − − − − − + + + + −
Arg-1 − − − − − − − − − −
NK 1.1 − − − − ++ − − − − −
CD11c − − − − + − − − − ++
Ly6G − − − − − − ++ ++ − −
SinglecF − − − − − − − ++ − −
Foxp3 − − − ++ − − − − − −
iNOS − − − − − − − − − −
CD62L − − − − − − − − − −
CD206 − − − − − − − − − −
The immunemarkers were assigned to each category of CD45+ cells according to their expression levels in that specific subpopulation.Marker intensity thresholds
used to discern between high and low marker expression are reported in Section 2.6 of methods. ++: high expression, +: intermediate expression, –: lack of
expression. iNOS, CD62L, and CD206 were not expressed on any cell population within the ascites.
the number or size of nodules between the experimental
groups was evident microscopically. Thus, further char-
acterization to assess the immune environment within
the tumor nodules was undertaken. In agreement with
the existing literature on immune cells present within
the OC TME,40 immunohistochemical analysis showed T
cells and antigen presenting cells (macrophages and DCs)
distributed throughout tumor nodules found on the sur-
face of the peritoneal membrane and scattered within the
abdomen. The presence of CD3+ tumor infiltrating lym-
phocytes (TILs) has been identified as an independent
prognostic factor in patients with epithelial OC.41–45 In
addition, antigen presenting cells such as tumor associ-
ated macrophages (TAMs) and DCs have significant roles
in the TME. In particular, TAMs, the most represented
cell population,46 have the potential to suppress or stimu-
late an anticancer response according to the effect the sur-
rounding microenvironment exerts on them.47,48
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F IGURE 7 Schematic of ascites immune cells and their interactions with the tumor. The interactions between ascites immune cells and
their potential effect on tumor cells. B220+/CD11b+/CD38+ B lymphocytes (A) and their CD25+/CD119+ regulatory B-cell subgroup (B)
exert antitumor and protumor activity, respectively. The role of CD4+ (C) and CD8+ (D) T cells in exerting cytotoxic activity towards the
tumor is linked to the antigen presenting capacity of CD11b+/CD11c+/CD44+ DCs (E). Eosinophils (G) and neutrophils (F) are linked to
protumoral and antitumoral properties, respectively. In parallel, monocytes and macrophages (H-J) exert either a tumor promoting or
suppressive effect according to the surrounding microenvironment
Focusing on the ascites, which is closely linked to an
altered immune environment within the peritoneal cavity
of advanced OC patients, further characterization was
undertaken. To comprehensively analyze the immune
landscape of the ascitic fluid collected from an ID8
ovarian cancer model, for the first time we exploited
mass cytometry. The 33 immune cell markers analyzed
allowed for the specific identification of distinct immune
cell populations and their linkage to pivotal functions
with respect to tumor progression. Compared to the
review from Wertel et al mentioned above, our results
showed similar overall percentages of CD8+ T cells, in
contrast with the lower percentages of CD4+ T cells and B
cells.49 The CD8+/CD4+ T-cell ratio of 1.76 we identified
was indicative of a higher overall presence of CD8+ T
cells compared to CD4+ cells, which is associated with
improved patient survival. This finding, together with the
expression of IFNγ, suggests effective immune stimulation
within the tumor and the development of cell-mediated
immunity. In contrast, Giuntoli et al demonstrated that
a high CD4+/CD8+ T-cell ratio is associated with poor
outcome done in patients with ovarian, primary peritoneal
or fallopian tube cancers, and that high concentrations of
interleukins 6 (IL-6) and 10 (IL-10) can help establish an
immunosuppressive climate thatmight lead to a decreased
activation of ascites-derived T cells.50
In Figure 7, we summarize the possible interactions
occurring between the immune cell populations identified
within the ascites and their effect on themetastatic tumors
in situ, based on cell-surface marker expression. The pres-
ence of CD45+B220+ B cells can be linked to both pro-
and antitumor responses due to their phenotypical and
functional variability, as confirmed by several other stud-
ies. Indeed, the B220+CD11b+MHC-II+ B-cell population
(7A) can have a positive or neutral prognostic effect,51,52
which can also be mediated by CD38 expression.53 In con-
trast to this, the presence of CD25+CD19+ B regulatory
cells (7B) is correlated with suppressed T cells responses
and poorer patient survival.54
Two additional markers, PD-1 and PD-L1, present on
both CD4+ (7C) and CD8+ T (7D) cells, have a pivotal role
in establishing efficient immunotherapeutic approaches,
after it was demonstrated that their inhibition can stop
cancer progression.55 Although clinical trials testing PD-1
and PD-L1 inhibitors have not yet yielded satisfactory
results in OC as single treatment,8,9 their use as combina-
torial treatment still holds promise. The prognostic value
of PD1+TILs, when colocalizedwith PD-L1 on cancer cells
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has been demonstrated supporting the PD-1 inhibitory
pathway as one mechanism they use to silence the
immune system during OC progression.56 In particular,
although tumors appear to be infiltrated by T cells at early
stages, a progressive reduction in the frequency of CD8+
T cells and CD8:Treg ratio was noticed at more advanced
advanced stages.57 Our findings have also attributed the
majority of PD-L1 expression to macrophages (7H) and,
together with the presence of cytolytic and regulatory TIL
subsets, link directly to survival potential.58 Macrophages,
identified through the coexpression of F4/80 and CD64,
were also positive for MHC-II, CD44, and CD80, with the
lattermarker suggesting anM1 phenotype, which has been
linked to increased inflammatory status47 and is specif-
ically correlated with a longer overall survival (OS) and
progression-free survival (PFS) in serous OC patients.59
Neutrophils (7F), identified by the presence of the
markers Ly6C and Ly6G (similar to other myeloid
derived populations such as eosinophils (7G) and mono-
cytes/macrophages), were also present.60 Neutrophils
have been connected to antitumor-promoting activity
in OC. Indeed, neutrophils isolated from the ascites
of a KRAS-ID8-induced mouse model showed KRAS-
dependent CD8+ T-cell activation through increased
recruitment of costimulatory molecules. On the con-
trary, neutrophil depletion (through administration of an
anti-Ly6G monoclonal antibody) led to marked tumor
progression.37 More recently, however, Ly6G-positive neu-
trophils have been reported to promote amicroenviroment
that is conducive of metastases spreading and accumula-
tion at specific sites.61
Dendritic cells, identified by the expression of CD11b+,
CD11c+, CD44+, andMHC-II (7E), are paramount players
in the activation of effective T-cell responses through their
antigen-presenting activity. Indeed, CD44 was found to be
pivotal in the formation of tight junctions between mature
DCs and T cells and to play a role in T-cell activation
as a consequence.62 However, DCs can undergo tumor-
mediated immunosupressive processes, such as the block-
age of their activity through the tumor-induced upregula-
tion of the unfolded protein response (UPR), as showed
by Cubillos-Ruiz et al.14 Moreover, Krempski et al also
found that tumor infiltrating, PD-1+/PD-L1+ DCs within
the ascites respond poorly to danger signal, suppress T-cell
activity and decrease T-cell infiltration within the tumor
masses.63
The immune cells identified within the ascites produced
in this model of HGSOC are linked to both pro- and antitu-
moral activity, indicating that this model represents a bal-
anced immune response to the tumor, or that the immuno-
suppressive effect of the tumor is yet to take hold. For
instance,while expression of the integrin, CD103, and tran-
scription factor, Tbet, associated with CD8+ T cells might
indicate a better prognosis,64–66 the high expression of
Ly6C on monocytes is a strong indicator of a TAM pheno-
type with strong immunosuppressive potential and poor a
prognosis.67,68
More generally, the presence of immune-active compo-
nents within the tumor nodules and the ascites raises the
question of why the therapeutic potential of immunother-
apies is still limited in OC settings. In this case, addi-
tional factors should be considered, including the so-called
tumormutation burden (TMB). TMB results from the iden-
tification and quantification of driver genesmutations that
are responsible for the production of neoantigens. The
increasing presence of neoantigens has been associated to
the activation of the antitumor immune response. For this
reason, TBM plays an important role in the progression of
a cancer with a high mutation load being associate to a
better prognosis.69 A recent investigation calculating TMB
in 397 patients with OC in the TCGA database revealed
that resting immune cells (B cells, B cells, CD4+ T cells,
Tregs, monocytes, mast cells, and neutrophils) likely infil-
trate tumors with low TMB, whereas activated immune
cells (CD4+ T cells, follicle-assisted T cells, proinflamma-
tory macrophages) infiltrate tumors with high TMB.70 In
other cases, some cell-based immunotherapies (such as
CAR-T) targeting a single tumor antigen often lose their
efficacy as the result of mutations occurring in tumor
cells, which impair specific antigen expression thus hin-
dering the effect of the therapy.71 In addition, cell therapeu-
tics often are subjected to the immunosuppressive envi-
ronment they meet following administration, which lim-
its their effectiveness in exerting an antitumor immune
response.28,72 The tryptophan catabolism offers another
example relevant in this context, as the tryptophan-
catabolizing enzyme indoleamine 2,3-dioxygenase (IDO)
has been found to be hyperactive in OC and linked to
the production of immunosuppressive catabolites and poor
patient survival.73 In addition, the cancer-induced acidic
environment has been shown to have a role in tumor recur-
rence, metastasis, and prognosis of cancer patients (due
to the high production of lactate).74 Furthermore, lactate
can also support cancer cell immune evasion by inhibit-
ing T-cell activation75 and dendritic cell antigen presenting
capacities.76
This work is the first to provide a multiparametric
and comprehensive characterization of the immune cell
landscape of the ascites collected from a preclinical model
of advanced OC. Published literature reports fragmented
information, as only single populations (such as CD4+ and
CD8+ T cells) have been so far identified and described.50
A more complete description has been offered by Wertel
et al who listed the percentages of the main cellular
components found in the peritoneal fluid of advanced OC
patients bymerging the information collected from several
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different studies.49 More recently, the panorama of the
ascites collected from HGSOC patients has been resolved
by applying single cell-RNA sequencing (scRNA-seq).77
In this study, the authors provided a broad view of the
different cell types in the ascites ecosystem,with particular
focus on malignant versus nonmalignant cells (analyzing
samples partially depleted of CD45+ immune cells).
The potential strength of the data we identified is there-
fore to demonstrate that mass cytometry provides a plat-
form for the comprehensive analysis of the immune cell
landscape within ascites, which would allow periodical
analysis of cellular and molecular changes in patients
with OC. In this regard, CyTOF holds the promise of
complementing personalized therapeutic approaches, and
potentially enabling real time tracking of the efficacy of
immunotherapeutics. Compared to scRNA-seq, CYTOF
offers the advantage of a higher throughput for the evalua-
tion of the TME in clinical samples, as it allows for a more
accurate targeting of immune cell subsets through the use
of >30 selected antigen markers. Moreover, CyTOF “nar-
row and distinct”78,79 data are generated from the anal-
ysis of over 250 000 cells, whereas transcriptome-based
platforms detect wider unbiased populations from several
thousands of cells.80,81
5 CONCLUSIONS
In this work, we provide, for the first time, a compre-
hensive characterization of the immune landscape of the
ascites collected from tumor-bearing mice, unveiling its
potential for clinical implementation. The continuous
analysis of interactions between immune cells in a cancer-
ous environment would significantly increase the number
of therapeutic options for the treatment of this malignancy
and offer a significant alternative for the evaluation of
ongoing therapies. Data presented in this study provemass
cytometry as a promising tool to facilitate this process,
with the potential to identify personalized therapeutic
targets and establish improved immunotherapy strategies.
In addition, the application of CyTOF on more complex
and genetically modified mice models, as well as on
patients’ derived samples, will also unveil new insights
into disease heterogeneity, pathology, and drug resistance,
and will expand our understanding of HGSOC.
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